After completion of this activity, the participant will:
- Be able to describe the symptoms of pediatric patients with MIS-C.
- Understand the similarities and differences between MIS-C and Kawasaki’s disease.
- Be familiar with the use of immunoglobulin for the treatment of Kawasaki disease and MIS-C, including typical dosing regimens.
- Be familiar with possible adjunctive treatments of Kawasaki Disease and MIS-C with immunomodulator medications including Anakinra and Tocilizumab.
Supported by an educational grant from: Kedrion Biopharma
Kenneth Paris, MD
Tamara Bradford, MD
Nursing 1 contact hour
ACPE 1 contact hour
1 IgCN® / IgCP® Recertification Units
This webinar was pre-recorded June 2020.